In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle ...

Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). This is an ASCO Meeting ...

rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...

Credit: ImmunityBio. Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist. The Food and Drug Administration (FDA) has approved Anktiva ® (nogapendekin alfa inbakicept-pmln) with ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...